Related references
Note: Only part of the references are listed.Exome Sequencing of Hepatoblastoma Reveals Novel Mutations and Cancer Genes in the Wnt Pathway and Ubiquitin Ligase Complex
Deshui Jia et al.
HEPATOLOGY (2014)
microRNAs miR-27a and miR-27b Directly Regulate Liver Dihydropyrimidine Dehydrogenase Expression through Two Conserved Binding Sites
Steven M. Offer et al.
MOLECULAR CANCER THERAPEUTICS (2014)
MicroRNAs as therapeutic targets in chemoresistance
Michela Garofalo et al.
DRUG RESISTANCE UPDATES (2013)
Genome-wide screening reveals that miR-195 targets the TNF-/NF-B pathway by down-regulating IB kinase alpha and TAB3 in hepatocellular carcinoma
Jie Ding et al.
HEPATOLOGY (2013)
Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Oktay Tacar et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2013)
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)
Joong-Won Park et al.
LIVER INTERNATIONAL (2013)
Integrated molecular analysis of clear-cell renal cell carcinoma
Yusuke Sato et al.
NATURE GENETICS (2013)
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Hui Ling et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Technologies for deriving primary tumor cells for use in personalized cancer therapy
Abhisek Mitra et al.
TRENDS IN BIOTECHNOLOGY (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Sidong Huang et al.
CELL (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Combinatorial drug therapy for cancer in the post-genomic era
Bissan Al-Lazikani et al.
NATURE BIOTECHNOLOGY (2012)
miR-34 – a microRNA replacement therapy is headed to the clinic
Andreas G. Bader
Frontiers in Genetics (2012)
MicroRNAs in the p53 network: micromanagement of tumour suppression
Heiko Hermeking
NATURE REVIEWS CANCER (2012)
Simultaneous Delivery of siRNA and Paclitaxel via a Two-in-One Micelleplex Promotes Synergistic Tumor Suppression
Tian-Meng Sun et al.
ACS NANO (2011)
An HNF4α-miRNA Inflammatory Feedback Circuit Regulates Hepatocellular Oncogenesis
Maria Hatziapostolou et al.
CELL (2011)
Cancer genomics: from discovery science to personalized medicine
Lynda Chin et al.
NATURE MEDICINE (2011)
MicroRNA pharmacogenomics: Post-transcriptional regulation of drug response
Jakob Lewin Rukov et al.
TRENDS IN MOLECULAR MEDICINE (2011)
MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy
Andrea L. Kasinski et al.
NATURE REVIEWS CANCER (2011)
MiR-199a-3p Regulates mTOR and c-Met to Influence the Doxorubicin Sensitivity of Human Hepatocarcinoma Cells
Francesca Fornari et al.
CANCER RESEARCH (2010)
Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion
Pei-Jer Chen et al.
LIVER INTERNATIONAL (2010)
Towards a knowledge-based Human Protein Atlas
Mathias Uhlen et al.
NATURE BIOTECHNOLOGY (2010)
Targeting microRNAs in cancer: rationale, strategies and challenges
Ramiro Garzon et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2010)
Correlations between RNA and protein expression profiles in 23 human cell lines
Marcus Gry et al.
BMC GENOMICS (2009)
miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation
Michela Garofalo et al.
CANCER CELL (2009)
MicroRNAs: Target Recognition and Regulatory Functions
David P. Bartel
CELL (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Statistical methods for analysis of high-throughput RNA interference screens
Amanda Birmingham et al.
NATURE METHODS (2009)
EPIC:: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
Alberto F. Sobrero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials
Pippa Newell et al.
JOURNAL OF HEPATOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Opinion - Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?
Christos Sotiriou et al.
NATURE REVIEWS CANCER (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
MicroRNA signatures in human cancers
George A. Calin et al.
NATURE REVIEWS CANCER (2006)
MicroRNA regulates the expression of human cytochrome P4501B1
Yuki Tsuchiya et al.
CANCER RESEARCH (2006)
p53 stabilization and transactivation by a von Hippel-Lindau protein
Jae-Seok Roe et al.
MOLECULAR CELL (2006)
Targeting multidrug resistance in cancer
G Szakács et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?
SB Baylin et al.
NATURE REVIEWS CANCER (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival
LD Miller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Combinatorial microRNA target predictions
A Krek et al.
NATURE GENETICS (2005)
Molecular mechanisms of drug resistance
DB Longley et al.
JOURNAL OF PATHOLOGY (2005)
The negative role of cyclin G in ATM-dependent p53 activation
T Ohtsuka et al.
ONCOGENE (2004)
Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants;: current state of knowledge
S Knasmüller et al.
TOXICOLOGY (2004)
Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma
DM Nanus et al.
CANCER (2004)
Prediction of mammalian microRNA targets
BP Lewis et al.
CELL (2003)
Reduced hepatic tumor incidence in cyclin G1-deficient mice
MR Jensen et al.
HEPATOLOGY (2003)
Cyclin G recruits PP2A to dephosphorylate Mdm2
K Okamoto et al.
MOLECULAR CELL (2002)
Share Paper
